ClinicalTrials.gg
RecruitingNCT07948083Updated Nov 19, 2026

KDTV001 Injection in Patients With Human Papillomavirus (HPV) Types 16, and/or 18, and/or 52 Associated Cervical High-Grade Squamous Intraepithelial Lesion .

A Phase 1/2 interventional study of KDTV001 in HPV (Human Papillomavirus)-Associated, HPV 16/18 and HPV 52, sponsored by Wuhan KadGeno Biotechnology Co., Ltd. Recruiting at 2 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Wuhan KadGeno Biotechnology Co., Ltd · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jan 2026, registered Nov 2026).
  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
304
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 69 studies in Papillomavirus Infections with a site in China — 27 open to participants now, 40 under way, 10 of them phase 3. Papillomavirus Infections · China.

Planned enrollment
26th of 45
304 · median 480
Started
2026
with 7 others
Phase 1/2
3 of 69
3 open now
Primary completion
2027-11
later than 24 of 39 live
Registered
67th of 69
by date

Among the 69 studies in Papillomavirus Infections with a site in China, this one is the 26th largest by planned enrollment of the 45 interventional ones that give a count, is one of 8 that started in 2026, is one of 3 in phase 1/2, reaches primary completion later than 24 of the 39 other live ones, and was the 67th registered.

Papillomavirus Infections

582 studies on the registry are indexed under Papillomavirus Infections; 134 are open to participants now.

Browse Papillomavirus Infections studies →

Open to participants now

27 of the 69 studies in Papillomavirus Infections with a site in China are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 88 Papillomavirus Infections studies recruiting now, 39 (44%) set no upper age limit and 44 (50%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Papillomavirus Infections with a site in China, or all of them as a file.
02

Study summary

KDTV001 Injection is a non-replicating adenovirus serotype 5 (Ad5)-based therapeutic HPV vaccine developed by Wuhan KadGeno Biotechnology Co., Ltd. It utilizes an engineered adenoviral vector expressing the HPV16/18/52 E6/E7 fusion protein under CMV promoter control, designed to inducing a robust cellular immune response that eradicates HPV-related lesions.

This is a Phase I, multicenter, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of KDTV001 Injection in participants with HPV types 16, and/or 18, and/or 52-associated cervical HSIL.

The study consists of three parts: dose escalation, an immunogenicity expansion cohort (Phase 1), and a dose expansion phase (Phase 2). In Phase 1a, 3+3 dose escalation of KDTV001 Injection will be conducted separately for IM and IC administration, with two ascending dose levels evaluated for each route. During the dose-escalation phase, if a dose cohort is assessed as safe by SRC, an immunogenicity expansion of 10-20 participants may be conducted. Based on Phase 1 safety and immunogenicity data, 1-2 dose levels will be selected for Phase 2 dose expansion for both IC and IM. In the Phase 2 dose-expansion phase, each dose cohort will enroll 30-50 participants. Both phases will consist of a screening period, a treatment and safety follow-up period, an end of study visit (EOS) and a long-term follow-up period.

03

Conditions studied

  • HPV (Human Papillomavirus)-Associated
  • HPV 16/18
  • HPV 52
  • Cervical High Grade Squamous Intraepithelial Lesion

Keywords

  • HPV16
  • HPV18
  • HPV 52
  • cervical HSIL
  • HPV therapeutic vaccine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cervical HSIL (defined as CIN 2 or 3), with the histological diagnosis confirmed by central pathology review within 12 weeks before the first study dose. Note: CIN 3 patients for whom immediate lesion removal is recommended by a clinician will not be enrolled in this study.
  • Confirmed cervical infection with HPV types 16, and/or 18, and/or 52 at screening by Central Lab. If there are other high-risk types of HPV infection, the investigator should assess based on the participant's infection history to exclude cases where such non-target types are persistent infections and the primary causes of disease.
  • All participants must have lesions of adequate size to ensure that a visible lesion remains after the screening .
  • Participants must have satisfactory colposcopy at screening, defined as full visualization of entire lesion and the squamo-columnar junction (Type I or II transformation zone).
  • Female participants aged ≥ 18 years.
  • No significant impairment of major organ functions, including but not limited to hematopoietic, cardiac, pulmonary, hepatic, and renal functions.
  • Female participants must meet one of the following criteria with respect their reproductive capacity:

a as defined by spontaneous amenorrhea for more than 12 months; b Surgically sterile due to absence of ovaries or due to a bilateral tubal ligation/occlusion performed more than 12 months prior to screening; c Women of Child Bearing Potential () must have a negative serum pregnancy test during the screening period; participants must agree to use reliable methods (barrier methods or abstinence) with their partners during the study and for at least 12 months after the last dose of product.

- Be willing to participate in this study and provide a signed form prior to participating in the trial.

Exclusion criteria

Exclusion Criteria:

  • Cervical adenocarcinoma in situ (AIS), atypical endometrial or glandular cells, or histopathological evidence of invasive cervical carcinoma on cervical within 12 weeks prior to the first study dose.
  • Have received pelvic radiotherapy within the past five years.
  • Have any active infection requiring systemic anti-infective treatment (routine prophylactic anti-infective treatment per the clinical trial institution is allowed) or an unexplained fever >38.5°C during the screening period.
  • Have more than three episodes of abnormal uterine bleeding within the recent three months.
  • Have a history of receiving adenovirus-based therapies within 6 months.
  • Participants with symptomatic vaginitis, including but not limited to bacterial, fungal, or trichomonal vaginitis. Participants may be eligible for enrollment after satisfactory treatment.
  • Participants who are pregnant, lactating, or unwilling to use protocol-defined at any time during the study;
  • History of other organ systems within the past five years, which in the investigator's judgment may interfere with study conduct or require systemic anticancer therapy during the study.
  • Poorly controlled diabetes (defined as fasting blood glucose ≥ 10 mmol/L) despite medication at screening.
  • Major surgery within 4 weeks prior to the first dose or anticipated during the study (excluding diagnostic procedures). Participants must have fully recovered from the toxicities and/or complications of the prior major surgery if conducted more than 4 weeks prior to the first study dose.
  • Participants with hereditary bleeding diathesis or coagulopathy, history of thrombosis or hemorrhage, or requirement for chronic anticoagulant therapy.
  • Have a history of severe cardiovascular or cerebrovascular diseases, including but not limited to:

    1. Severe cardiac conduction abnormalities requiring clinical intervention (e.g. ventricular arrhythmias requiring treatment, second- or third-degree atrioventricular block).
    2. interval ≥ 460 ms on resting 12-lead .
    3. Acute coronary syndrome, congestive heart failure, aortic dissection, cerebrovascular accident, or other Grade 3 or higher cardiovascular events occurring within six months prior to the first study dose.
    4. (NYHA) functional classification ≥ Class II OR (LVEF) \<50%, OR other investigator-assessed high-risk structural heart diseases.
    5. Clinically uncontrolled hypertension.
  • Participants with disorders or immunodeficiency conditions, or who have received hematopoietic stem cell transplantation, or solid organ transplantation.
  • Asplenia, functional asplenia, or any condition resulting in absence or removal of the spleen.
  • Have any of the following serum virology findings:

    1. Positive antibody test; OR
    2. Positive Treponema pallidum antibody; OR
    3. Active infection defined as:

      HBsAg positive AND HBV-DNA >500 IU/mL or above institutional detection limit if higher than standard threshold (only when the lower limit of detection threshold of the clinical trial institution is higher than 500 IU/mL)

    4. Active infection defined as: Anti-HCV positive AND HCV-RNA above institutional detection limit Note: Individuals receiving prophylactic antiviral therapies other than interferon are allowed to be enrolled.
  • Have uncontrolled seizures, central nervous system disorders, or psychiatric conditions resulting in loss of cognitive capacity.
  • Have a history within the past year of, or are currently experiencing, any other uncontrolled medical conditions, including but not limited to cardiac, hepatic, pulmonary, renal, gastrointestinal, neurological, psychiatric, metabolic disorders.
  • Have received any blood products within three months prior to enrollment.
  • Require concomitant use of antiviral therapy OR have received antiviral medications within two weeks prior to the first administration of the study drug.
  • Have received any vaccination within four weeks prior to enrollment.
  • History of previous therapeutic HPV vaccination (individuals who have been immunized with licensed prophylactic HPV vaccines are not excluded).
  • Tattoos, scars, or active dermatologic lesions or rashes at the injection site that interfere with local safety assessments.
  • Currently receiving OR have received following doses of systemic therapy prior to the first administration of the product:

    1. Long-term corticosteroid therapy: > 10 mg/day prednisone or equivalent within 30 days prior to the first study dose;
    2. Short-term corticosteroid therapy: ≥ 1 mg/kg/day prednisone or equivalent for ≥ 2 courses, each lasting >3 days, within 30 days prior to the first study dose.

Note: Topical, ocular, intra-articular, nasal, or inhaled corticosteroids are permitted.

  • Have a history of severe allergies or known allergic constitution.
  • Other conditions deemed unsuitable for study enrollment by the investigator.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
304 participants (estimated)

Study arms

  • Experimental
    Cohort A Dose Level 1

    KDTV001:1 × 10\^11 VP, IM, W0, W4, W12

    Drug: KDTV001

  • Experimental
    Cohort A Dose Level 2

    KDTV001: 3 × 10\^11 VP, IM, W0, W4, W12

    Drug: KDTV001

  • Experimental
    Cohort B Dose Level 1

    KDTV001: 1 × 10\^10 VP, IC, W0, W4, W12

    Drug: KDTV001

  • Experimental
    Cohort B Dose Level 2

    KDTV001: 3 × 10\^10 VP, IC, W0, W4, W12

    Drug: KDTV001

Interventions

  • DrugKDTV001

    KDTV001 Injection is a non-replicating adenovirus serotype 5 (Ad5)-based therapeutic HPV vaccine developed by Wuhan KadGeno Biotechnology Co., Ltd. It utilizes an engineered adenoviral vector expressing the HPV16/18/52 E6/E7 fusion protein under CMV promoter control, designed to inducing a robust cellular immune response that eradicates HPV-related lesions.

06

What researchers measure

Primary outcomes

  1. Phase 1: Incidence of Any Adverse Events (AEs), Treatment related AEs (TRAEs) and Serious Adverse Events (SAEs) Following Investigational Treatment for the Duration of the Study

    Percentage of participants with AE/TRAE/SAE in FAS population

    Time frame: From enrollment to 2 years after the first dose.

  2. Phase 2: Percentage of Participants With No Evidence of Cervical HSIL on Histology and No Evidence of HPV-16 and HPV-18 and HPV-52 in Cervical Samples

    Participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL, no evidence of HPV-16 and HPV-18 and HPV-52 at the Week 36 time frame, and participants in which excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or low-grade intraepithelial lesion (LSIL). HPV testing will be performed using the cobas® assay and a second assay kit manufactured in China to identify HPV 52.

    Time frame: From enrollment to 36 weeks after the first dose.

Secondary outcomes

  1. Phase 1: HPV clearance rates after dosing;

    Incidence of Participants with no evidence of HPV-16 and HPV-18 and HPV-52 at Week 12, 24, and 36, and Week 52, 78, and 104 if the participants do not have excisional treatment. HPV testing will be performed using the cobas® assay and a second assay kit manufactured in China to identify HPV 52.

    Time frame: From enrollment to 104 weeks after the first dose.

  2. Phase 2: The immunogenicity of KDTV001 injection;

    Immunogenicity within 52 weeks after the first dose: cellular immune responses against E6/E7 of HPV16/18/52, including enzyme-linked immunospot (ELISPOT) assay and flow cytometry, etc.

    Time frame: From enrollment to 52 weeks after the first dose.

  3. Companion biomarkers of KDTV001

    * HPV integration; * Patient HLA typing; * p16, HPV E6/E7 and Ki67 gene expression analysis as well as immune infiltration analysis, etc. of cervical tissues; * Cervical gene methylation level; * Cell-free Human Papillomavirus DNA (cfDNA-HPV), peripheral blood immune cell subsets, and related antibody production (e.g. peripheral blood antibodies to HPV16/18/52 E6/E7 and viral vector (Ad5)).

    Time frame: From enrollment to 52 weeks after the first dose.

07

Study locations

2 of 2 sites recruiting
  • TongJi Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
    Recruiting
    • Nan Yu, Prof · Contact
    • Nan Yu, Prof · Principal investigator
    • Gang Chen, Prof · Principal investigator
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
    Recruiting
    • Peng Wu, Prof · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Nov 2027, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 19, 2026
StartActual
Jan 6, 2026
Primary completionEst.
Nov 30, 2027
CompletionEst.
Jan 30, 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07948083
Lead sponsor
Wuhan KadGeno Biotechnology Co., Ltd
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Jan 6, 2026
Primary completion
Nov 30, 2027 (estimated)
Completion
Jan 30, 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Yanyan Zhang, MMed
Contact
Linda@whkdws.com
+8618607163222

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion